Abstract
This review summarizes the mechanisms, applications, and adverse effects of colorful dyes, such as Castellani’s paint, gentian violet, and potassium permanganate, as well as two other vibrant topical creams—vitamin B12 and indigo naturalis. Certain dyes such as Castellani’s paint, gentian violet, and potassium permanganate were once commonplace topical therapies for cutaneous infections; these dyes are brightly colored on application and have been suggested to be efficacious and well tolerated through case studies as well as controlled studies. Moreover, topical vitamin B12 and topical indigo naturalis creams for atopic dermatitis and psoriasis have been extensively studied through multiple controlled trials and may also be effective, with minimal adverse effects. Understanding the composition and mechanism of action has helped guide the development of these therapies.
Similar content being viewed by others
References
Shah MK. Castellani’s paint. Indian J Dermatol Venereol Leprol. 2003;69(5):357–8.
Litt JZ. Alternative topical therapy. Dermatol Clin. 1989;7(1):43–52.
Castellani A. Carbol-fuchsin paints in the treatment of certain cases of epidermophytosis. Am Med. 1928;34:351–6.
Seale ER, Clark WA. Treatment of intertriginous moniliasis. South Med J. 1948;41(10):926–30.
Babakurban ST, Topal O, Aydin E, et al. Therapeutic effect of Castellani’s paint in patients with an itchy ear canal. J Laryngol Otol. 2016;130(10):934–8.
Sugathan P, Najeeba R, Neelakantam, et al. An unusual side effect of Castellani’s paint. Indian J Dermatol Venereol Leprol. 1990;56:317–8.
Riyaz N. Castellani’s paint. Indian J Dermatol Venereol Leprol. 2004;70(2):119.
Field LM. Castellani’s paint without fuchsin. Arch Dermatol. 1979;155(11):1287.
Arnold HL Jr. Castellani’s paint without fuchsin. Arch Dermatol. 1979;155(11):1287.
Balabanova M, Popova L, Tchipeva R. Dyes in dermatology. Clin Dermatol. 2003;21(1):2–6.
Maley AM, Arbiser JL. Gentian violet: a 19th century drug re-emerges in the 21st century. Exp Dermatol. 2013;22(12):775–80.
Docampo R, Moreno SNJ. The metabolism and mode of action of gentian violet. Drug Metab Rev. 1990;22:161–6.
Bakker P, Van Doorne H, Gooskens V, et al. Activity of gentian violet and brilliant green against some microorganisms associated with skin infections. Int J Dermatol. 1992;31(3):210–3.
Wainwright, M. Dyes for the medical industry. In: Clark M, editor. Handbook of textile and industrial dyeing. Woodhead Publishing; Cambridge, 2011. https://www.woodheadpublishing.com
Riley K, Flower AH. A comparison of the inhibitory effect of Castellani’s paint and of gentian violet solution on the in vitro growth of Candida albicans. J Invest Dermatol. 1950;15(5):355–62.
Taguchi S, Saji M, Sakisaka M, et al. Studies of selective bactericidal effects of various dye preparations on MRSA. Chemotherapy. 1993;41:935–40.
Saji M. Effect of gentiana violet against methicillin-resistant Staphylococcus aureus (MRSA) [in Japanese]. Kansenshogaku Zasshi. 1992;66(7):914–22.
Saji M, Taguchi S, Hayama N, et al. Effect of gentian violet on the elimination of methicillin-resistant Staphylococcus aureus (MRSA) existing in the decubitus region [in Japanese]. Nihon Ronen Igakkai Zasshi. 1993;30(9):795–801.
Brockow K, Grabenhorst P, Abeck D, et al. Effect of gentian violet in Staphylococcus aureus-colonized atopic eczema. Dermatology. 1999;199(3):231–6.
Wald ER, Snyder MJ, Gutberlet RL. Group B beta-hemolytic streptococcal colonization: acquisition, persistence, and effect of umbilical cord treatment with triple dye. Am J Dis Child. 1977;131(2):178–80.
Zupan J, Garner P, Omari A. Topical umbilical cord care at birth. Cochrane Database Syst Rev. 2004;(3):CD001057.
Faber HK, Dickey LB. The treatment of thrush with gentian violet. JAMA. 1925;85(12):900–1.
White DJ, Johnson EM, Warnock DW. Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata. Genitourin Med. 1993;69(2):112–4.
Nyst MJ, Perriens JH, Kimputu L, et al. Gentian violet, ketoconazole and nystatin in oropharyngeal and esophageal candidiasis in Zairian AIDS patients. Ann Soc Belg Med Trop. 1992;72(1):45–52.
Mukherjee PK, Chen H, Patton LL, et al. Topical gentian violet compared to nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1-infected participants. AIDS. 2017;31(1):81–8.
Bhandarkar SS, MacKelfresh J, Fried L, et al. Targeted therapy of oral hairy leukoplakia with gentian violet. J Am Acad Dermatol. 2008;58(4):711–2.
Slotkowski EL, Redondo D. Mucosal irritation following the use of gentian violet. Am J Dis Child. 1966;112(1):40–2.
Verbov J. Oral irritation with gentian violet. Br Med J. 1976;2(6036):639.
Arbiser JL. Gentian violet is safe. J Am Acad Dermatol. 2009;61(2):359.
World Health Organization. WHO model list of essential medicines, 20th list. Geneva: World Health Organization; 2017. Available at: http://www.who.int/iris/handle/10665/273826. Accessed 30 Apr 2019.
World Health Organization. WHO model prescribing information: drugs used in skin diseases. Geneva: World Health Organization; 1997.
Hu N, Wu XH, Liu R, et al. Novel application of vacuum sealing drainage with continuous irrigation of potassium permanganate for managing infective wounds of gas gangrene. J Huazhong Univ Sci Technol Med Sci. 2015;35(4):563–8.
Burns T, Breathnach S, Cox N, et al. Rook’s textbook of dermatology. 8th ed. Oxford: Wiley-Blackwell Scientific Publications; 2010.
Delgado-Enciso I, Madrigal-Perez VM, Lara-Esqueda A, et al. Topical 5% potassium permanganate solution accelerates the healing process in chronic diabetic foot ulcers. Biomed Rep. 2018;8(2):156–9.
Stücker M, Pieck C, Stoerb C, et al. Topical vitamin B12: a new therapeutic approach in atopic dermatitis—evaluation of efficacy and tolerability in a randomized placebo-controlled multicentre clinical trial. Br J Dermatol. 2004;150(5):977–83.
Howe EE, Dooley CL, Geoffroy RF, et al. Percutaneous absorption of vitamin B12 in the rat and guinea pig. J Nutr. 1967;92(2):261–6.
Yamashiki M, Nishimura A, Kosaka Y. Effects of methylcobalamin (vitamin B12) on in vitro cytokine production of peripheral blood mononuclear cells. J Clin Lab Immunol. 1992;37(4):173–82.
Sakane T, Takada S, Kotani H, et al. Effects of methyl-B12 on the in vitro immune functions of human T lymphocytes. J Clin Immunol. 1982;2(2):101–9.
Hanifin JM. Atopic dermatitis: new therapeutic considerations. J Am Acad of Dermatol. 1991;24(6 Part 2):1097–101.
Nistico SP, Del Duca E, Tamburi F, et al. Superiority of a vitamin B12-barrier cream compared with standard glycerol-petrolatum-based emollient cream in the treatment of atopic dermatitis: a randomized, left-to-right comparative trial. Dermatol Ther. 2017;30(5):e12523.
Januchowski R. Evaluation of topical vitamin B12 for the treatment of childhood eczema. J Altern Complement Med. 2009;15(4):387–9.
Stankler L. The vitamin B12 level in psoriatic skin and serum. Br J Dermatol. 1969;81(12):911–8.
Del Duca E, Farnetani F, De Carvalho N, et al. Superiority of a vitamin B12-containing emollient compared to a standard emollient in the maintenance treatment of mild-to-moderate plaque psoriasis. Int J Immunopathol Pharmacol. 2017;30(4):439–44.
Stücker M, Memmel U, Hoffmann M, et al. Vitamin B12 cream containing avocado oil in the therapy of plaque psoriasis. Dermatology. 2001;203(2):141–7.
Jansen T, Romiti R, Kreuter A, et al. Rosacea fulminans triggered by high-dose vitamins B6 and B12. J Eur Acad Dermatol Venereol. 2001;15(5):484–5.
Lin YK, See LC, Huang YH, et al. Comparison of indirubin concentrations in indigo naturalis ointment for psoriasis treatment: a randomized, double-blind, dosage-controlled trial. Br J Dermatol. 2017;178(1):124–31.
Chiang YR, Li A, Leu YL, et al. An in vitro study of the antimicrobial effects of indigo naturalis prepared from Strobilanthes formosanus Moore. Molecules. 2013;18(11):14381–96.
Lin YK, Chen HW, Leu YL, et al. Indigo naturalis upregulates claudin-1 expression in human keratinocytes and psoriatic lesions. J Ethnopharmacol. 2013;145(2):614–20.
Lin YK, Leu YL, Yang SH, et al. Anti-psoriatic effects of indigo naturalis on the proliferation and differentiation of keratinocytes with indirubin as the active component. J Dermatol Sci. 2009;54(3):168–74.
Hsieh WL, Lin YK, Tsai CN, et al. Indirubin, an acting component of indigo naturalis, inhibits EGFR activation and EGF-induced CDC25B gene expression in epidermal keratinocytes. J Dermatol Sci. 2012;67(2):140–6.
Kim MH, Choi YY, Yang G, et al. Indirubin, a purple 3,2-bisindole, inhibited allergic contact dermatitis via regulating T helper (Th)-mediated immune system in DNCB-induced model. J Ethnopharmacol. 2013;145(1):214–9.
Gamret AC, Price A, Fertig RM, et al. Complementary and alternative medicine therapies for psoriasis: a systematic review. JAMA Dermatol. 2018;154(11):1330–7.
Cheng HM, Wu YC, Wang Q, et al. Clinical efficacy and IL-17 targeting mechanism of Indigo naturalis as a topical agent in moderate psoriasis. BMC Complement Altern Med. 2017;17(1):439.
Lin YK, Chang CJ, Chang YC, et al. Clinical assessment of patients with recalcitrant psoriasis in a randomized, observer-blind, vehicle-controlled trial using indigo naturalis. Arch Dermatol. 2008;144(11):1457–64.
Lin YK, See LC, Huang YH, et al. Comparison of refined and crude indigo naturalis ointment in treating psoriasis: randomized, observer-blind, controlled, intrapatient trial. Arch Dermatol. 2012;148(3):397–400.
Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–5.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No sources of funding were received to prepare this article.
Conflict of interest
Gaurav Agnihotri and Sumul Gandhi report no conflicts of interest. Peter A. Lio has served as a consultant or advisor to Abbvie, Altus, AOBiome, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin BioScience, Galderma, IntraDerm, Johnson and Johnson, La Roche-Psay, Menlo, Micreos, Mission, Pfizer, Pierre Fabre, Realm, Regeneron/Sanofi-Genzyme, Theraplex, UCB, and Unilever; has served as a speaker for Pfizer, Regeneron/Sanofi-Genzyme, La Roche-Posay, and Pierre Fabre; and has been an investigator and received research grants/funding from AOBiome, Regeneron/Sanofi-Genzyme, and Abbvie.
Rights and permissions
About this article
Cite this article
Agnihotri, G., Gandhi, S. & Lio, P.A. Colorful dyes and other vibrant topical creams as treatments for dermatological conditions. Drugs Ther Perspect 35, 491–499 (2019). https://doi.org/10.1007/s40267-019-00665-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-019-00665-1